Hemophilia is a type of bleeding disorder that causes the blood to take a long time to clot, and occurs almost exclusively in males. People with hemophilia B have a deficiency in clotting factor IX, a specific protein in the blood.¹ According to the World Federation of Hemophilia, approximately one in 50,000 people globally² have hemophilia B, including nearly 4,110 people living with hemophilia B in the U.S.³

People with hemophilia face specific risks and need to be careful not to cause injury to their bodies, as injuries can prompt a bleed. Bleeding in hemophilia can be potentially life-threatening. While people with hemophilia do not bleed faster than people without hemophilia, they do tend to bleed longer because of their inability to clot, increasing their risk of internal injury.¹

In the last century alone, the treatment of hemophilia has undergone many changes. In the 1950s, plasma was first used to treat people with hemophilia. ⁴ In the 1960s, researchers began experimenting with concentrates of factor, ⁴ and in the early 1990s, the first recombinant factor products became available. ⁴ Innovations continue to be explored in the manufacturing and purification processes of hemophilia treatments.

A documentary, titled “Pushing Boundaries: How Science Impacted the Treatment of Hemophilia B” presents a brief history of hemophilia B treatment and tells the story of the development of recombinant factor IX and the approval of BeneFIX® Coagulation Factor IX (Recombinant). BeneFIX is a recombinant coagulation factor IX product indicated for the control, prevention and perioperative management of bleeding episodes in adult and pediatric patients with hemophilia B. BeneFIX received FDA fast track approval in the U.S. on February 11, 1997. This year, BeneFIX celebrates its 15^th anniversary.

The documentary also features interviews with researchers and hemophilia B patients, while illustrating the innovative science brought forth by researchers in developing BeneFIX.

BeneFIX was developed by Genetics Institute (now Pfizer) in Andover, Massachusetts, at a time when few people had ever manufactured and formulated a recombinant protein clotting factor. The development of BeneFIX pioneered many of the recombinant protein drug production techniques commonly used today. BeneFIX is currently marketed in 34 countries and has been used by more than 30,000 patients worldwide.⁵

Hemophilia B patient Phil H. began using BeneFIX following its approval in 1997. Patients like Phil and other members of the hemophilia B community have provided feedback over the years that has not only contributed to the development of BeneFIX, but also to its latest product offerings. These offerings include the development of the Rapid Reconstitution (R2) kit, the ability to store at room temperature, and the 3000 IU dosage strength.

“Growing up, it was challenging to deal with my bleeds,” said Phil. “I’m thankful that my voice and the voice of patients like me was heard.”

For more information about BeneFIX and to view the documentary, please visit www.benefix.com. To learn more about hemophilia B, please visit www.benefix.com.

About BeneFIX